Chardan analyst Geulah Livshits revised the price forecast for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) from $45 to $46, while keeping a Buy rating.

The analyst says that while patient variability makes individual assay benefit interpretation complex, Rocket is evaluating multiple parameters to identify optimal endpoints, expecting clearer signals with longer follow-up and its natural history study data.

With no further dose escalation planned, Rocket aims to discuss pivotal trial design (potentially leveraging NH data) at the 8e13 dose with regulators; accelerated approval is possible, adds the analyst.

Livshits writes that the data collectively suggests RP-A601 is providing some benefit, though the best measure is still to be determined.

Consequently, the analyst is increasing their Probability of Success (PoS) for the program to 30% from 20%.

RCKT Price Action: Rocket Pharmaceuticals shares are down 2.90% at $6.53 at publication on Friday.

Read Next:

• Rocket Pharmaceuticals’ Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

photo: Shutterstock